~~<i id='C95FDF5462'><strike id='C95FDF5462'><tt id='C95FDF5462'><pre id='C95FDF5462'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：comprehensive 2025-09-05 13:28:25 - browse：812

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Covid silver lining: Unprecedented look at human immune system

focus

explore

entertainment

focus

AdobeEvenamongapparentlyhealthychildren,Blackpatientsarealmostthreeandahalftimesmorelikelytodiewithi

WSS

Why depression after traumatic brain injury is distinct

Multiple sclerosis has subtypes with different best treatments: study

Steward Health Care Massachusetts hospitals face fiscal disaster

Bird flu in dairy cattle: New measures to control spread to humans

Researchers test human milk's ability to repair gut microbiome

How to save health care price transparency rules

explore

entertainment

focus

In Memoriam: Notable people who died in 2023

Young boy dies in trial for Pfizer Duchenne gene therapy

Medical records are filled with copy

First Opinion on colorectal cancer screening: letter and response

In age of alternative facts, a scholarly course on calling out crap

First Opinion on colorectal cancer screening: letter and response

23andMe had bad news about my health. I wish a person had delivered it

Researchers test human milk's ability to repair gut microbiome

Medical records are filled with copy

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

focus

First U.S. drug developed to treat liver disease MASH is approved

Researchers test human milk's ability to repair gut microbiome

Drug companies' payments and gifts affect physicians' prescribing

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

As AI in medicine takes off, can 'human in the loop' prevent harm?

Young boy dies in trial for Pfizer Duchenne gene therapy

focus

explore

entertainment

focus